Institutional
Athyrium Capital Management, LP
CIK 0001728001
$8.7M
Reported AUM
2
Positions
Q3 2024
Period
2024-11-12
Filed
Editorial summary
Summary for Athyrium Capital Management, LP · Q3 2024 is not yet generated. It will appear here after the next nightly run.
Portfolio · Q3 2024
Top holdings
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | — | Biora Therapeutics Inc. | — | — | — | — | $5.5M | 63.12% | — | HELD |
| 2 | PBYI | PUMA BIOTECHNOLOGY INC | $7.93 | 0.51% | 157.00% | 4.23% | $3.2M | 36.88% | — | HELD |
Source: SEC EDGAR · accession 0001123292-24-000336. 13F discloses long positions only — shorts, foreign equities, and options are excluded.